Neurocrine Biosciences (NASDAQ:NBIX) Given New $180.00 Price Target at Barclays

Neurocrine Biosciences (NASDAQ:NBIX) had its price objective lifted by stock analysts at Barclays from $169.00 to $180.00 in a report issued on Friday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Barclays‘s target price suggests a potential upside of 18.20% from the stock’s current price.

Other analysts also recently issued research reports about the stock. JPMorgan Chase & Co. upped their price target on shares of Neurocrine Biosciences from $169.00 to $173.00 and gave the stock an “overweight” rating in a report on Wednesday, July 10th. BMO Capital Markets upped their price objective on shares of Neurocrine Biosciences from $129.00 to $138.00 and gave the stock a “market perform” rating in a research report on Thursday, May 2nd. Wedbush reissued an “outperform” rating and set a $152.00 price objective on shares of Neurocrine Biosciences in a report on Wednesday, May 29th. Cantor Fitzgerald reiterated an “overweight” rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, July 25th. Finally, Canaccord Genuity Group lifted their target price on shares of Neurocrine Biosciences from $154.00 to $164.00 and gave the stock a “buy” rating in a research note on Thursday, May 2nd. Six investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $155.44.

Neurocrine Biosciences Price Performance

NASDAQ NBIX traded down $0.86 on Friday, reaching $152.29. The stock had a trading volume of 196,337 shares, compared to its average volume of 821,443. The company has a market cap of $15.33 billion, a P/E ratio of 41.93 and a beta of 0.37. The firm has a fifty day moving average of $139.54 and a two-hundred day moving average of $138.26. Neurocrine Biosciences has a 1-year low of $100.52 and a 1-year high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Wednesday, May 1st. The company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $1.04 by ($0.62). Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. The business had revenue of $515.30 million during the quarter, compared to analyst estimates of $512.21 million. Research analysts predict that Neurocrine Biosciences will post 4.22 EPS for the current fiscal year.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Stephen A. Sherwin sold 40,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $133.46, for a total value of $5,338,400.00. Following the sale, the director now owns 26,504 shares of the company’s stock, valued at approximately $3,537,223.84. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Neurocrine Biosciences news, Director Stephen A. Sherwin sold 40,000 shares of Neurocrine Biosciences stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $133.46, for a total value of $5,338,400.00. Following the completion of the transaction, the director now directly owns 26,504 shares of the company’s stock, valued at approximately $3,537,223.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Julie Cooke sold 900 shares of the company’s stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $150.04, for a total transaction of $135,036.00. Following the sale, the insider now owns 18,202 shares in the company, valued at $2,731,028.08. The disclosure for this sale can be found here. Insiders have sold a total of 80,709 shares of company stock valued at $11,009,150 over the last ninety days. 4.30% of the stock is currently owned by company insiders.

Institutional Trading of Neurocrine Biosciences

A number of institutional investors have recently bought and sold shares of NBIX. Vanguard Group Inc. increased its position in Neurocrine Biosciences by 2.3% during the first quarter. Vanguard Group Inc. now owns 9,930,926 shares of the company’s stock valued at $1,369,673,000 after acquiring an additional 220,598 shares during the last quarter. Brown Advisory Inc. grew its holdings in Neurocrine Biosciences by 2.2% during the 4th quarter. Brown Advisory Inc. now owns 1,113,413 shares of the company’s stock valued at $146,703,000 after purchasing an additional 23,831 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Neurocrine Biosciences by 1.4% in the second quarter. Bank of New York Mellon Corp now owns 934,404 shares of the company’s stock worth $128,639,000 after buying an additional 13,069 shares during the period. Los Angeles Capital Management LLC grew its position in Neurocrine Biosciences by 66.0% in the 4th quarter. Los Angeles Capital Management LLC now owns 918,391 shares of the company’s stock valued at $121,007,000 after acquiring an additional 364,986 shares during the last quarter. Finally, Vestal Point Capital LP purchased a new stake in shares of Neurocrine Biosciences during the fourth quarter valued at $105,408,000. 92.59% of the stock is currently owned by institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.